Tarsus Pharmaceuticals, Inc. TARS R&D credit carryforward
R&D credit carryforward at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-K, filed February 23, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s r&d credit carryforward.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s r&d credit carryforward?
- Tarsus Pharmaceuticals, Inc. (TARS) reported r&d credit carryforward of $6.99M in Q4 2025.
- How has Tarsus Pharmaceuticals, Inc.'s r&d credit carryforward changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s r&d credit carryforward decreased by 19.2% year-over-year, from $8.64M to $6.99M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s r&d credit carryforward?
- Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s r&d credit carryforward has grown at a 58.0% compound annual growth rate (CAGR), from $710K to $6.99M.
- What does r&d credit carryforward mean?
- This represents the value of tax credits generated from research and development activities that can be applied to reduce future tax liabilities. These assets arise when R&D spending exceeds current tax capacity, allowing the company to carry forward the benefit to future profitable periods. It is a key indicator of the potential tax shield available to the company as it scales its commercial operations.